Form 4: Whitehawk CFO Executes Tax-Related Stock Sale

Whitehawk Therapeutics CFO Scott M. Giacobello sold 218,600 shares to cover tax obligations related to RSU vesting.

Summary

• CFO Scott M. Giacobello sold a total of 218,600 shares of Whitehawk Therapeutics common stock.
• The transactions occurred on April 15, 2026 (77,000 shares at $3.86) and April 16, 2026 (141,600 shares at $4.13).
• The sales were conducted via a broker-assisted arrangement specifically to satisfy tax withholding obligations resulting from the vesting of restricted stock units.
• Following these transactions, the reporting person retains beneficial ownership of 295,224 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is a routine administrative action related to tax obligations rather than a discretionary divestment.

Positives

• The sale was non-discretionary, intended solely to satisfy tax liabilities associated with equity compensation.
• The reporting person maintains a significant remaining equity stake of 295,224 shares.

Negatives

• The reduction in direct share ownership by a key executive may be perceived as a decrease in personal financial alignment with the company's long-term performance.

Risks

• Market perception of insider selling can occasionally lead to short-term volatility in share price.

Future Outlook

No forward-looking guidance or operational outlook was provided in this filing.

Management Comments

• The filing notes that the sales were broker-assisted to satisfy tax withholding obligations in connection with the vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that tax-related sell-offs by executives are standard corporate practice and generally do not signal a lack of confidence in the company's strategic direction.

Comparison to Industry Standards

• The transaction aligns with standard executive compensation practices where equity awards are liquidated to cover mandatory tax withholding upon vesting.

Stakeholder Impact

• Shareholders should view this as a routine tax-related transaction with no material impact on company operations or governance.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Whitehawk Therapeutics, WHWK, Insider Trading, CFO, Form 4, Equity Compensation, Tax Withholding